Clinical trials: Androgen Deprivation Therapy, open to volunteers
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
Prostate Cancer Patients, Androgen Deprivation Therapy
Effects of Combined Training in Prostate Cancer Patients
Prostate cancer is the most prevalent type among men in Brazil, after non-melanoma skin cancer. One of the main treatment approaches is androgen suppression therapy (AST), which, although effective in controlling tumor growth…
- Trial name
- Proactive (NCT07680920)
- Testing
- Combined training
- Volunteers
- 46 people
- Sponsor
- Universidade Federal de Santa Catarina
Prostate Cancer
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer.
- Trial name
- (RANGER) (NCT07313241)
- Testing
- Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy.
- Trial name
- NCT06172283
- Testing
- Intermittent Fasting
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- State University of New York at Buffalo
Prostate Cancer
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
The goal of this clinical trial is to evaluate the outcomes of a shorter treatment duration (12 months) with an androgen receptor pathway inhibitor (ARPI), in this study Apalutamide or Enzalutamide, in patients with low-volume…
- Trial name
- Apa/Enza-short (NCT07260435)
- Testing
- ADT plus only 12 months of ARPI, ADT plus continued ARPI
- Where
- 26 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Nick Beije
Prostate Cancer, Localized Prostate Carcinoma
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT.
- Trial name
- NCT07455903
- Testing
- Leuprolide, Degarelix, Relugolix
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baptist Health South Florida
Salivary Gland Neoplasm Duct
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma…
- Trial name
- NCT06348264
- Testing
- Rezvilutamide, Leuprolide Acetate
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Peking University First Hospital
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.
- Trial name
- NCT07241416
- Testing
- Rezvilutamide Tablets, Enzalutamide Soft Capsules
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
High-Risk Localized Prostate Cancer
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6…
- Trial name
- NCT07550517
- Testing
- EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Metabolic Syndrome
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A.
- Conditions
- Prostate Cancer, Metabolic Syndrome, Obesity, Cardiovascular Morbidity
- Trial name
- NCT05802121
- Testing
- Apple Cider Vinegar
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Western University
Cancer Survivor, Obesity
Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer
This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors.
- Conditions
- Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma
- Trial name
- NCT03880422
- Testing
- Dietary Intervention, Educational Intervention, Exercise Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Prostate CA
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06861192
- Testing
- Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy, radical prostatectomy
- Where
- China
- Volunteers
- 83 people
- Sponsor
- baotai Liang
Prostate Cancer
Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy
The goal of the clinical trial is to find out whether transdermal estradiol will reduce the adverse effects of androgen deprivation therapy in prostate cancer patients.
- Trial name
- ESTRACISE (NCT06271551)
- Testing
- Transdermal estrogen, Active Comparator: Androgen deprivation therapy, Resistance training
- Volunteers
- 310 people
- Sponsor
- Central Finland Hospital District
Metastatic Hormone-sensitive Prostate Cancer, Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
The purpose of this study is to investigate the clinical efficacy and safety of darolutamide combined with androgen deprivation therapy (ADT) and different dose-intensity docetaxel chemotherapy in the treatment of patients with…
- Trial name
- NCT07031258
- Testing
- Dose of docetaxel
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Prostate Cancer (Adenocarcinoma)
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
This study aims to assess the impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on bone quality in patients with prostate cancer.
- Trial name
- NCT06838520
- Testing
- Bone health assessment
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Castration-resistant Prostate Cancer
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
- Trial name
- NCT06636123
- Testing
- Investigational Agent Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer, Muscle Loss
Resistance Exercise, IL-7 and Immune Phenotypes in Prostate Cancer
Hormone therapy for prostate cancer typically causes significant muscle loss. Skeletal muscle releases Interleukin-7 (IL-7), a signalling protein that supports the production of new immune cells.
- Trial name
- NCT07724080
- Testing
- Supervised Resistance Exercise Programme
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Bath
Prostate Cancer
SRT Versus SRT+ADT in Prostate Cancer
To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of intermediate unfavorable and a subclass of high-risk patients treated with prostate Stereotactic radiotherapy (SRT).
- Trial name
- SPA (NCT05019846)
- Testing
- Triptorelin Embonate, Bicalutamide 50 mg
- Where
- Italy
- Volunteers
- 310 people
- Sponsor
- Marco Lorenzo Bonu
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
The goal of this clinical trial is to study definitive external beam radiation therapy together with drugs called androgen deprivation therapy (ADT) in patients with prostate cancer.
- Trial name
- SENTRY (NCT07364071)
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego